AC Immune (ACIU) Cash from Operations (QoQ) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.36% |
| Sep 30, 2025 | -19.32% |
| Jun 30, 2025 | 9.11% |
| Mar 31, 2025 | -417.86% |
| Dec 31, 2024 | 141.50% |
| Sep 30, 2024 | -120.21% |
| Jun 30, 2024 | 6,783.25% |
| Mar 31, 2024 | 106.36% |
| Dec 31, 2023 | -21.03% |
| Sep 30, 2023 | 3.37% |
| Jun 30, 2023 | 13.13% |
| Mar 31, 2023 | -2.95% |
| Dec 31, 2022 | -25.88% |
| Sep 30, 2022 | 30.70% |
| Jun 30, 2022 | 19.28% |
| Mar 31, 2022 | -33.14% |
| Dec 31, 2021 | -19.19% |
| Sep 30, 2021 | 10.13% |
| Jun 30, 2021 | 8.38% |
| Mar 31, 2021 | 9.19% |
| Dec 31, 2020 | -24.64% |
| Sep 30, 2020 | -9.80% |
| Jun 30, 2020 | -54.09% |
| Mar 31, 2020 | 22.18% |
| Dec 31, 2019 | -174.52% |
| Sep 30, 2019 | 215.17% |
| Jun 30, 2019 | -122.63% |
| Mar 31, 2019 | 675.84% |
| Dec 31, 2018 | 4.40% |
| Sep 30, 2018 | -66.05% |
| Jun 30, 2018 | 48.50% |
| Mar 31, 2018 | -100.05% |
| Dec 31, 2017 | 197.52% |
| Sep 30, 2017 | -322,694.54% |
| Jun 30, 2017 | 22.72% |
| Mar 31, 2017 | -69.09% |
| Dec 31, 2016 | -179.82% |
| Sep 30, 2016 | 1,662.97% |
| Jun 30, 2016 | 106.43% |
| Mar 31, 2016 | -37.35% |